Literature DB >> 21420570

In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?

Ana Espinel-Ingroff1, Emilia Cantón.   

Abstract

The echinocandins anidulafungin, caspofungin, and micafungin have a broad and similar spectrum of in vitro and in vivo activity against most Candida spp. Minimal inhibitory concentrations (MICs) for Candida spp. are usually below 1 μg/mL for most isolates. The exceptions are Candidaparapsilosis and C. guilliermondii. Species-specific clinical breakpoints (CBPs) and epidemiologic cutoff values (ECVs) have been proposed by the Clinical and Laboratory Standards Institute (CLSI) for the eight most common Candida spp. versus each echinocandin; these values are useful to detect in vitro antifungal resistance (CBPs) and to identify isolates harboring fks mutations or having reduced susceptibility (ECVs). This paper presents a review of the literature (2006-2010) regarding the in vitro activity similarities or differences among the three echinocandins against Candida spp.; different parameters or measurements of in vitro potency were evaluated. The focus of the review is the non-Candida albicans species.
Copyright © 2011 Elsevier España S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420570     DOI: 10.1016/S0213-005X(11)70002-7

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  4 in total

1.  Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  C F Neoh; E Senol; A Kara; E C Dinleyici; S J Turner; D C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-28       Impact factor: 3.267

2.  Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.

Authors:  Elisabetta Spreghini; Fiorenza Orlando; Maurizio Sanguinetti; Brunella Posteraro; Daniele Giannini; Esther Manso; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

3.  Candida guilliermondii: biotechnological applications, perspectives for biological control, emerging clinical importance and recent advances in genetics.

Authors:  Nicolas Papon; Vincenzo Savini; Arnaud Lanoue; Andrew J Simkin; Joël Crèche; Nathalie Giglioli-Guivarc'h; Marc Clastre; Vincent Courdavault; Andriy A Sibirny
Journal:  Curr Genet       Date:  2013-04-25       Impact factor: 3.886

4.  In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.

Authors:  Fabiola Fernández-Silva; Michaela Lackner; Javier Capilla; Emilio Mayayo; Deanna Sutton; Mariana Castanheira; Annette W Fothergill; Cornelia Lass-Flörl; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.